Tesamorelin and AOD-9604 Stack: How These Two Peptides Compare and Combine

The tesamorelin and AOD-9604 stack combines a prescription GHRH analog with a research peptide that both get marketed for fat loss, and the two work through very different pathways. Tesamorelin is FDA-approved to reduce visceral abdominal fat in adults with HIV-associated lipodystrophy, while AOD-9604 is not approved for any human use and has produced only modest results in clinical trials. No published human study has tested the two peptides together, so every stack protocol circulating online is extrapolated from single-agent research.

What the Tesamorelin and AOD-9604 Stack Is

Searches for tesamorelin aod 9604 usually come from people looking for a stronger fat-loss protocol than either peptide delivers alone. The logic is straightforward: tesamorelin raises growth hormone and IGF-1, while AOD-9604 is designed to act on fat metabolism without touching IGF-1 at all.

Tesamorelin is a synthetic 44-amino-acid copy of growth hormone-releasing hormone (GHRH). It signals the pituitary to release more of your own growth hormone, which is why it produces measurable changes in body composition rather than just appetite suppression.

AOD-9604 is a modified fragment of human growth hormone, specifically the 176-191 region, often sold as the fat-burning fragment. It was engineered to separate growth hormone's fat-metabolizing effects from its growth and blood-sugar effects, and it does not meaningfully raise IGF-1.

For many users, an aod 9604 stack is a support peptide layered on top of a growth-hormone-releasing agent such as tesamorelin, sometimes with MOTS-c added for metabolic support. Choosing to stack two peptides is not the same as having evidence that the stack works.

Tesamorelin vs AOD-9604: Key Differences

In practice, the aod 9604 vs tesamorelin comparison comes down to hormonal activity, evidence quality, and regulatory status.

Feature	Tesamorelin	AOD-9604
Peptide class	GHRH analog	Modified hGH fragment 176-191
Main mechanism	Stimulates pituitary GH release and raises IGF-1	Mimics part of GH's lipolytic action without raising IGF-1
FDA status	Approved as Egrifta SV for HIV-associated visceral adiposity	Not approved for any human use
Typical research dose	1.4 mg or 2 mg subcutaneously once daily	300 mcg to 1 mg per day in studies
Human evidence	Multiple randomized trials showing reduced visceral fat	Small trials with modest, inconsistent weight-loss effects
Sport status	Banned by WADA	Banned by WADA

Tesamorelin is the only one of the two compounds with FDA approval, and that approval is limited to a specific patient population with a specific diagnosis. AOD-9604 has no approved human indication anywhere in the world, which means any product sold directly to consumers is unregulated and unverified.

Reported Stack Dosing and Protocols

Because there is no combination trial, dosing information comes from single-agent studies and online protocols. A commonly shared aod-9604 tesamorelin stack dosage is 1.4 mg of tesamorelin injected at night plus 300 mcg of AOD-9604 in the morning on an empty stomach.

Compound	Reported dose	Typical timing	Notes
Tesamorelin	1.4 mg to 2 mg daily	Before bed, fasted	Prescription only; mirrors trial protocols
AOD-9604	300 mcg to 1 mg daily	Morning, fasted	No approved dose exists
MOTS-c (optional)	5 mg to 10 mg daily	Pre-workout or morning	Early-stage research only

None of these numbers come from a study of the combination, and self-reported protocols vary widely. Anyone considering this kind of regimen should discuss it with a physician who can monitor IGF-1, blood glucose, and liver markers.

What Human Research Actually Shows

Tesamorelin has the stronger evidence base of the two. Randomized trials in adults with HIV-associated lipodystrophy showed meaningful reductions in visceral adipose tissue over 26 to 52 weeks, along with improvements in trunk fat and patient-reported belly image distress.

Those benefits fade when the drug is stopped. In follow-up data, visceral fat drifted back toward baseline within months of discontinuation, which is consistent with how GHRH analogs work.

AOD-9604's human data are far weaker. Small randomized trials reported modest or statistically inconclusive weight changes, and reviewers have repeatedly concluded that the peptide's fat-loss effect in people is small at best.

That is the main reason people pair aod 9604 with tesamorelin: the hope that a stronger agent compensates for a weaker one. No trial has confirmed that this works, and no trial has measured whether the combination raises the risk of side effects.

No published human trial has tested tesamorelin and AOD-9604 together, so any stack protocol is extrapolated from single-agent research.

Safety, Side Effects, and Legal Status

Tesamorelin is a prescription drug with real side effects. Reported issues include injection-site reactions, joint and muscle pain, peripheral swelling, and increases in IGF-1 that may affect glucose tolerance. It is not appropriate for people with active cancer, pituitary tumors, or pregnancy.

AOD-9604 has a much shorter safety record. Trials lasting around 12 weeks reported it as generally well tolerated, but there is no long-term human safety data, and research-grade vials sold online are not guaranteed to contain what the label claims.

Both peptides are banned in sport by the World Anti-Doping Agency. Athletes subject to testing can be sanctioned for either compound, including AOD-9604, which has appeared on prohibited lists for years.

Anyone using either peptide should tell their physician, because both can interact with blood sugar and hormone regulation. Neither peptide replaces diet, resistance training, or medical care for obesity, and a doctor can review whether a patient qualifies for an approved therapy such as a GLP-1 medication.

RELATED PEPTIDE TOPICTesamorelin research

COMMON QUESTIONS

Frequently Asked Questions

Is the tesamorelin and AOD-9604 stack safe?

There is no human trial data on the combination, so its safety profile is unknown. Tesamorelin is a prescription drug that can cause injection-site reactions, joint pain, swelling, and changes in IGF-1 and blood sugar. AOD-9604 has only short-term safety data, and unregulated research vials may not match their labels. Talk with a physician before using either peptide.

How do people dose AOD-9604 with tesamorelin?

There is no established combination dose. Published tesamorelin trials used 1.4 mg or 2 mg daily by subcutaneous injection, while AOD-9604 studies typically used 300 mcg to 1 mg per day. Online protocols often split them by timing, with tesamorelin at night and AOD-9604 in the morning. These numbers are not validated for stacking.

Does AOD-9604 actually burn fat?

Human trials of AOD-9604 have shown only modest, inconsistent weight-loss effects, and the peptide is not FDA-approved for weight loss or any other use. Animal studies were more encouraging than the human data. AOD-9604 is also banned in sport by the World Anti-Doping Agency.